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Abstract
Background: Numerous epidemiological studies have documented that obesity is associated with hepatocellular
carcinoma (HCC). The aim of this study was to investigate the biological actions regulated by leptin, the obesity
biomarker molecule, and its receptors in HCC and the correlation between leptin and human telomerase reverse
transcriptase (hTERT), a known mediator of cellular immortalization.
Methods: We investigated the relationship between leptin, leptin receptors and hTERT mRNA expression in HCC
and healthy liver tissue samples. In HepG2 cells, chromatin immunoprecipitation assay was used to study signal
transducer and activator of transcription-3 (STAT3) and myc/mad/max transcription factors downstream of leptin
which could be responsible for hTERT regulation. Flow cytometry was used for evaluation of cell cycle
modifications and MMP1, 9 and 13 expression after treatment of HepG2 cells with leptin. Blocking of leptin’s
expression was achieved using siRNA against leptin and transfection with liposomes.
Results: We showed, for the first time, that leptin’s expression is highly correlated with hTERT expression levels in
HCC liver tissues. We also demonstrated in HepG2 cells that leptin-induced up-regulation of hTERT and TA was
mediated through binding of STAT3 and Myc/Max/Mad network proteins on hTERT promoter. We also found that
leptin could affect hepatocellular carcinoma progression and invasion through its interaction with cytokines and
matrix mettaloproteinases (MMPs) in the tumorigenic microenvironment. Furthermore, we showed that histone
modification contributes to leptin’s gene regulation in HCC.
Conclusions: We propose that leptin is a key regulator of the malignant properties of hepatocellular carcinoma
cells through modulation of hTERT, a critical player of oncogenesis.
Background
Obesity is an important risk factor for many types of
cancer, including hepatocellular carcinoma (HCC) [1,2].
Among adipocytokines, that are the main body weight
regulators, leptin, the 16-KDa nonglycosylated protein
product of the Ob gene, has a central role [3,4]. It is a
multifunctional peptide hormone with a wide range of
biological activities including neuroendocrine function
[5], angiogenesis [6,7], bone formation [8] and modula-
tion of immune responses [9,10]. Leptin exerts its
actions through its six isoforms of receptors, which are
membrane spanning glycoproteins with cytoplasmic
domains of varying length [11].
Leptin’s signaling is thought to be transmitted mainly
by the Janus-activated Kinase/signal transducers and
activators of transcription (JAK/STAT) pathway [12]. Of
the seven human STAT genes, STAT3 has been shown
to be activated in a wide variety of human tumors and
tumor cell lines and its activation is accompanied by
increased expression of important cell cycle and survival
regulators, such as cyclin D1, c-myc and survivin
[13,14]. Many STAT3 target genes are key components
of the regulation of cell cycle progression from G1 to S
phase [15].
At present, a biological explanation for the association
between obesity and HCC is not known. It seems that
there is a strong relationship between adipocytokines,
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have not been clarified yet. Hepatocarcinogenesis is a
multi-step process involving different genetic alterations
that ultimately lead to malignant transformation of the
hepatocyte [16,17]. One of the molecular events that
underlie the multigenetic process of hepatocarcinogen-
esis is activation of human telomerase reverse transcrip-
tase (hTERT)/telomerase which is normally suppressed
in most human somatic tissues after birth [18,19].
In the present study we investigated, for the first time,
the relationship between leptin, leptin receptors and
hTERT mRNA expression in HCC. We also attempted
to elucidate on the molecular pathways that may med-
iate this interaction by investigating the regulation of
hTERT gene promoter by histone acetylation status as
well as STAT3 and c-myc transcription factors. Finally,
the biological effects of leptin in HCC progression
through inflammatory cytokines such as IL-1, IL-6, TGF
and MMPs were assessed.
Methods
Subjects
The study protocol conformed to the ethical guidelines
of the 1975 Declaration of Helsinki as reflected in a
priori approval by the local Ethical Committee of the
University Hospital of Larissa and by the Institutional
Review Board (Institute of Medical Science, University
of Tokyo). Specifically, control liver tissue specimens
were obtained after oral informed consent from 23
patients (eleven male, twelve female; mean age 54.9
years, range 37-84 years) during an operation that was
performed for cholelithiasis (cholecystectomy). All these
individuals had apparently no evidence of chronic liver
disease and normal ALT (alanine aminotransferase)
values (26.6 ± 4.9 U/L), tested negative for HBsAg, anti-
HCV and anti-HIV antibodies and denied ever having
used hepatotoxic drugs, herbals, or having abused alco-
hol or injected drugs.
Twenty three liver tissue samples from HCC patients
were used in this study, which were purchased from
Biomax (US Biomax Inc, MD, USA) and were also pro-
vided from the University of Tokyo (thirteen male, ten
female; mean age: 58.4 years; range: 45-75 years). Writ-
ten informed consent was obtained from the patients.
The diagnostic criteria for HCC were based on the con-
clusions of the Barcelona-2000 EASL conference while
the histological diagnosis was made according to the
AJCC/UICC classification system [20,21]. From the 23
HCC tissue samples, 8 were due to HBV-related cirrho-
sis and 15 were due to HCV-related cirrhosis.
Cell cultures, reagents and treatments
HepG2 hepatocellular carcinoma cells were used and
were cultured in RPMI 1640 medium (Gibco,
Paisley, Scotland, UK) supplemented with 10% fetal
bovine serum (Gibco, Paisley, Scotland, UK), L-Glu-
tamine 2 mM (Gibco, Paisley, Scotland, UK), peni-
cillin 100 IU/ml and streptomycin 100 μg/ml
(Gibco, Paisley, Scotland, UK), at 37°C in 5% CO2.
After 16 hours of serum starvation, the culture
media were changed to serum free media containing
leptin. Cultures were treated with human recombi-
nant leptin at 25, 50, 100, 200 ng/ml (R&D Systems,
Minneapolis, MN, USA). Cell culture supernates
were removed, centrifuged and stored at -80°C until
assayed. Leptin, TGF-b1, IL-6, IL-1b and IL-1a were
measured using commercially available assays
according to manufacturers’ instructions (R&D Sys-
tems, Minneapolis, MN, USA).
RNA isolation and Real-time PCR
Each sample was homogenized and total cellular RNA
was extracted, reverse transcribed to cDNA and real-
time PCR was performed for leptin, OB-Rs, OB-Rl and
telomerase, as previously described [22,23]
Immunohistochemistry for hTERT, leptin and OB-R
Immunohistochemical staining for hTERT and leptin
expression was completed using antihuman hTERT anti-
body (PC563) (EMD Biosciences, Merck KGaA, Darm-
stadt, Germany), A20 leptin polyclonal Ab (pAb) (Santa
Cruz Biotechnology, Santa Cruz, USA), or the M18 ObR
pAb, (Santa Cruz Biotechnology) according to standard
IHC procedures [24].
Cell viability
Cell viability was determined with the MTT assay using
the TACS MTT kit (R&D Systems, Minneapolis, MN,
USA) according to manufacturer’s instructions. HepG2
proliferation was assessed in the presence of increasing
concentrations of leptin (0-200 ng/ml) or in the absence
of leptin (siRNA treatment against leptin). Cell prolifera-
tion was examined at 12h, 24h and 48h after addition of
leptin.
TRAP assay
TRAP (telomeric repeat protocol assay) assay was per-
formed using the TeloTAGGG telomerase PCR ELISA
PLUS kit (Roche, Indianapolis, IN, USA) as previously
described [25].
Small interfering RNA treatment
HepG2 cells were transfected with dsRNA oligonucleo-
tides for leptin using Lipofectamine 2000 reagent (Invi-
trogen, Carlsbad, CA). Different doses of siRNAs were
administered at first for either 24, 48, 72 hours, in order
to define the optimum dosage and time for a satisfying
silencing, controlled by real time RT-PCR and ELISA
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were used in order to verify the absence of toxicity for
the different doses administered.
Chromatin immunoprecipitation
Chromatin Immunoprecipitation was performed using a
ChIP assay kit (Upstate USA, Inc., Charlottesville, VA,
USA). The immunoprecipitated DNAs were amplified
by PCR with the primers indicated below. For leptin
promoter (proximal promoter, forward: 5′-CCCTCTAA
CCCTGGGCTTC-3′; reverse: 5′-ACTATGGCGCAAG-
GACCAG-3′), for hTERT promoter (set 1 for STAT3,
forward: 5′-CCAAACCTGTGGACAGAACC-3′; reverse:
5′-AGACTGACTGCCTCCATCGT-3′,s e t2f o rS T A T 3 ,
forward: 5′- GGGGTGTCTTCTGGGTATCA-3′; reve-
rse: 5′-AAGGGCTGTGTTTGTGAATTG-3′,p r o x i m a l
hTERT promoter, forward: 5′- TGCCCCTTCACCTTC-
CAGCTC-3′;r e v e r s e :5 ′- GTGGCCGGGGCCAGG
GCTT-3′).
Flow cytometry
Cell cycle distribution was determined by flow cytome-
try. At least 10.000 events were collected for each sam-
ple. Intracellular staining antibodies against MMP-1,
MMP-9, proMMP-13 were used for cytometric analysis
of HepG2 cells according to manufacturers instructions
(R&D Systems, Minneapolis, MN, USA). Effect of leptin
treatment (50, 200 ng/ml for 48 h and 100 ng/ml for 2
months) and leptin siRNA on MMP-1, MMP-9 and
MMP-13 protein levels were evaluated.
Statistical analysis
Statistical analysis was performed as previously
described [22].
Results
Leptin, OB-Rl and OB-Rs expression in liver tissues of
HCC patients
In order to test the malignant dynamics of leptin in
liver, we evaluated leptin and leptin receptors mRNA
and protein expression using real-time RT-PCR and
immunohistochemistry (IHC) respectively, in HCC and
non-HCC liver tissues. Leptin was not expressed in any
healthy liver tissue, but was expressed in 18 out of 23
HCC tissues as evaluated by RT-PCR or IHC (78.2%).
More specifically, regarding real-time PCR data, mean
leptin levels were 6.1 ± 3.21 × 10ˉ², while no difference
in leptin expression levels was found between the HBV
and HCV subgroups of the HCC group. Significant dif-
ferences were observed between the mean OB-Rl and
OB-Rs mRNA levels in HCC liver tissues (0.726 ± 0.155
and 0.227 ± 0.092, respectively,) and healthy tissues
(0.0165 ± 0.0031 and 0.0292 ± 0.00194, respectively)
(p < 0.001) (Figure 1).
Correlation of leptin expression with hTERT expression
Interestingly, taking into account our previous findings
in chronic viral hepatitis and HCC (altered leptin and
hTERT mRNA levels in HCC or chronic viral hepatitis
liver samples compared to healthy liver samples), we
proceeded to determine whether there is an association
between leptin and hTERT mRNA expression [22,23].
We found a significant association between leptin and
hTERT mRNA expression only in HCC livers (r = 0.79,
p < 0.05).
Leptin affects hTERT expression levels and TA in
HCC cells
The association between leptin and hTERT/TA in HCC
samples prompted us to study the effect of leptin
administration on hTERT in HepG2 cells. When HepG2
cells were treated with leptin concentrations of 50, 100,
200 ng/ml for 48 hours and 100 ng/ml for 2 months, we
observed that hTERT mRNA levels and TA were signifi-
cantly increased (Figure 2a, b). We then blocked leptin’s
expression in HepG2 cells using siRNA against leptin
and transfection with liposomes and did not observe a
significant decrease in hTERT mRNA levels and TA
(Figure 2a, b).
The JAK/STAT3 pathway and the Myc/Max/Mad network
are important for leptin-mediated up-regulation of
hTERT expression
To gain insight into the mechanism underlying the lep-
tin-mediated transactivation of hTERT promoter on
HCC cells, we next examined signal transduction path-
ways possibly involved in mediating leptin’s action. The
presence of STAT3 binding sites in hTERT promoter
and the role of STAT3 in leptin response, suggest that
these sites may be involved in leptin’s control of hTERT
expression. Chromatin immunoprecipitation assays were
performed with all putative STAT3 binding sites. In
HepG2 cells, STAT3 was found to be associated with
site 1 and 2 within hTERT promoter. Short and long
term leptin stimulation (200 ng/ml for 48 h and 100 ng/
ml for 2 months) of HepG2 led to the recruitment of
STAT3 at the hTERT promoter (Figure 3a). In addition,
using ChIP analysis we obtained direct evidence for the
interaction between c-Myc, Mad1, Max and acetylated
H3 with hTERT promoter. In untreated HepG2 cells an
hTERT signal was observed in the Mad and Max immu-
noprecipitations, whereas in leptin treated cells (200 ng/
ml for 48 h ) a strong hTERT signal was ditected in the
Myc/Max immunoprecipitations (Figure 3b). Interest-
ingly, long term (two months with 100 ng/ml) leptin
treatment of HepG2 attenuated the binding of Myc/Max
to hTERT promoter. On the other hand acetylated H3
was found to bind on hTERT promoter only after long
term leptin treatment (2 months) (Figure 3b).
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Figure 1 Leptin, OB-Rl or OB-Rs expression levels in healthy and HCC liver tissues. Comparison of liver tissues of healthy individuals and
HCC patients with respect to mean leptin, OB-Rl, OB-Rs expression levels (leptin or OB-Rl or OB-Rs mRNA copies/PBGD copies) obtained after
real time RT-PCR analysis. Bars, means ± standard deviation,*, p < 0.05 compared to healthy liver tissues.
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Figure 2 Leptin promotes hTERT expression and TA in HepG2 cells. (a) Total RNA was isolated and its expression was evaluated using real-
time RT-PCR, to determine changes in the level of hTERT mRNA expression after normalization to PBGD expression. All data were presented as a
fold induction relative to untreated cells. Columns, mean of three independent experiments done in triplicate; bars, SD; *, p < 0.05 compared to
untreated cells, (b) Telomerase activity after leptin and leptin siRNA treatment as mentioned above.
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modulates the cell cycle of HCC cells
As leptin-mediated overexpression of hTERT might lead
to tumorigenic growth and deregulated cell cycle, we
investigated, next, the effect of leptin on HepG2 cells
proliferation using the MTT assay. Leptin stimulated the
growth of HepG2 cells in a time- and dose- dependent
manner. Furthermore leptin’s knockdown was correlated
with a notable reduction in proliferation rate (Figure 4a).
Additionally, we observed that treatment with leptin
deregulated HepG2 cell cycle, as it increased the propor-
tion of HepG2 in S and G2/M phase, while leptin’s
knockdown decreased the proportion of HepG2 in S and
G2/M phase compared to untreated cells (Figure 4b).
Leptin could affect tumor progression and invasion
dynamics in HCC
The possible role of the inflammatory cytokines in the
development and spread of cancer cells led us to examine
the involvement of leptin in the production of IL-1a, IL-
1b, IL-6 and TGF-b1 by human HCC cells. We found
that leptin enhanced only the production of IL-6, after 72
hours treatment and repressed the production of TGF-b1
in a time- and dose dependent manner (Figure 5a, b).
Regarding IL-1a, there was no significant difference
between stimulated with leptin and untreated HepG2
cultures (data not shown). Leptin siRNA treatment did
not affect the production of the above mentioned cyto-
kines (data not shown). As metalloproteinases (MMPs)
have been linked with the promotion of tumor
invasiveness, we next examined leptin’s effect in the pro-
duction of MMPs-1, -9 and -13 by HepG2 cells. We
found that leptin decreased MMP-1 levels and increased
MMP-13 and MMP-9 levels in a dose- and time- depen-
dent manner (Figure 5c). siRNA treatment against leptin
in HepG2 cells resulted in a significant induction of
MMP-1 and reduction of MMP-9 and MMP-13 expres-
sion levels (p < 0.001).
Histone H3 modifications contribute to leptin gene
regulation in HCC cells
In order to investigate whether the amount of acetylated
H3 interacting with leptin’s proximal promoter was cor-
related with the regulation of leptin gene transcription,
we used trichostatin A (TSA), an inhibitor of histone dea-
cetylation. TSA treatment (200, 500, 1000 nM) of HepG2
cells increased leptin’s mRNA expression in a dose
dependent manner ( ~2, ~3.5, ~8 fold increase in leptin’s
mRNA expression respectively). The same treatment also
upregulated leptin’s protein expression, but not in the
same pattern (Figure 6a). We tested the acetylation levels
of histone H3 and found that in the absence of TSA, H3
binding on the promoter of leptin was undetectable,
whereas in TSA treated (500 nM) HepG2 cells, a strong
leptin promoter signal was detected in the acetylated H3
immunoprecipitations (Figure 6b).
Discussion
Numerous studies have established a relationship
between obesity and various disease states including
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Input IgG STAT3
hTERT site 1
hTERT site 2
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hTERT 
promoter
B
Figure 3 Leptin enhances the binding of STAT3, Myc, H3 to hTERT promoter. (a) ChIP assay was performed using anti-STAT3 antibody or
irrelevant anti-immunoglobin G antibody as negative control. Input samples are total genomic DNAs used as control for the PCR. PCR primers
covering the STAT3 binding sites of hTERT promoter region were used to detect promoter fragment in immunoprecipitates. Leptin (-), untreated
cells, Leptin (+), 200 ng/ml for 48 h, Leptin (++), 100 ng/ml for 2 months. (b) ChiP assay was performed using anti-Mad1, anti-Max, anti-Myc and
anti-acetylated H3 antibodies or irrelevant anti-IgG antibody as negative control. PCR primers covering proximal hTERT promoter were used.
Leptin (-), untreated cells, Leptin (+), 200 ng/ml for 48 h, Leptin (++), 100 ng/ml for 2 months
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Page 5 of 10cancer. Obesity has been suggested as an important risk
factor for both cirrhotic and non-cirrhotic hepatocellular
carcinoma, which constitutes the third leading cause of
cancer death worldwide [2,26]. It has also been sug-
gested that there is a strong link between leptin and
cancer growth and development, with increasing evi-
dence on the involvement of leptin on breast, ovarian,
endometrial, colon, and prostate cancer [27-33].
Recently, high leptin and leptin receptor expression
levels were correlated with the degree of angiogenesis in
human HCC [34]. In addition, leptin-mediated neovas-
cularization showed an effective role of leptin in the
development of hepatocarcinogenesis in non-alcoholic
steatohepatitis [35]. In the present study, in order to
determine the contribution of the leptin system in HCC
progression, we investigated the expression of leptin and
its receptors in HCC and normal liver tissues. The
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Figure 4 Leptin is mitogenic for HCC cells. (a) Effect of leptin on HepG2 cell proliferation. Cell number is expressed as percentage of control,
i.e. cell cultures that was untreated. Columns, mean of three independent experiments done in triplicate; bars, SD, *, p < 0.001 compared to
untreated cells (for siRNA experiment compared to siRNA control), (b) Leptin icreased the fraction of HepG2 cells in S and G2/M phases of the
cycle. HepG2 cells were exposed to leptin (50, 200 ng/ml for 48 h and 100 ng/ml for to 2 months) and leptin siRNA. Columns, mean of three
independent experiments done in triplicate; bars, SD, *, p < 0.05 compared to untreated cells (for siRNA experiment compared to siRNA control).
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Figure 5 Leptin regulates inflammatory cytokines and MMPs production in HepG2 cells. (a, b) Effect of leptin treatment (200 ng/ml) at
different times (24, 48, 72 h) on IL-6 and TGF-b1 production. Columns, mean of three independent experiments done in triplicate; bars, SD, *,
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liver, accompanied by the elevated OB-Rl and OB-Rs
mRNA expression levels in HCC, support the role of
leptin system in the development of HCC [36,37]. As
the high expression of leptin and its receptors in HCC
liver tissues was not found to be correlated with BMI
we could assume that the production of leptin in HCC
liver is not directly regulated by the adipose tissue
deposit, but also reflects the intricate interactions taking
place into the tumorigenic microenvironment.
It has previously been reported that hTERT mRNA
overexpression and elevation of TA might be some of
the processes involved in tumour initiation and progres-
sion in the liver [17,23,38]. Our results demonstrate, for
the first time to our knowledge, a strong correlation
between leptin expression and hTERT levels in HCC
liver tissues. Moreover, we found that leptin was capable
of a direct beneficent action upon hTERT mRNA and
TA in HepG2 cells. The fact that leptin’s knockdown by
siRNA did not decrease hTERT mRNA levels and TA,
suggests that the basal hTERT levels are not only under
the control of the leptin system. These findings are in
accordance with a very recent study by Ren et al. in
MCF-7 cells and reveal that hTERT is probably a target
gene for leptin and strengthen the role of leptin as a
pivotal factor in HCC [39].
Previous studies have shown that STAT3 is a key med-
iator of critical cancer cell processes, as it promotes cell
cycle progression and survival, stimulates angiogenesis
and generally promotes malignant transformation
[13,14,40,41]. Very recently, hTERT has been identified
as a direct downstream gene of STAT3 in both tumor
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Figure 6 Histone acetylation regulates leptin expression in HepG2 cells. (a) TSA treatment (200, 500, 1000 nM) of HepG2 cells for 24 h
increased leptin’s mRNA and protein expression. Columns, means of three independent experiments done in triplicate; bars, SD, *, p < 0.001
compared to untreated cells, (b) After TSA treatment H3 was found acetylated in proximal leptin promoter.
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Page 8 of 10and normal cells [42]. Taking into account that STAT3 is
downstream of leptin and upstream of hTERT, we inves-
tigated the hypothesis that the STAT3 signalling pathway
plays a crucial role in leptin-mediated hTERT expression.
Our findings showed a recruitment of STAT3 in two
binding sites in hTERT promoter under leptin stimula-
tion of HCC cells, supporting the key role of STAT3 sig-
naling in leptin induced hTERT expression.
A number of interesting reports have proposed the
identification of the Myc/Max/Mad network, as a mole-
cular switch that either interacts with the core promoter
to activate hTERT transcription (Myc/Max) or promotes
down regulation of hTERT mRNA production (Mad/
Max) [43-45]. In the present study we demonstrated, for
the first time, an association between the switch from
Mad1/Max to Myc/Max binding and activation of
hTERT transcription after leptin treatment of HepG2
cells and additionally an expanded interaction of Myc/
Max complex accompanied by an increase in H3 acety-
lation in hTERT proximal promoter after long term lep-
tin treatment of HCC cells. As the long term leptin
treatment of HepG2 cells did not extend further the
mRNA production of hTERT and TA, we assume that
leptin-mediated hTERT overexpression is also under the
consistent control of post-transcriptional regulators.
HCC arises most frequently in the setting of chronic
liver inflammation and moreover cytokines, such as IL-
6, produced in the inflammatory tumor microenviron-
ment stimulate the growth of cancer cells and tumor
invasiveness [46]. In the present study, we demonstrated
the ability of leptin to increase IL-6 secretion in HCC
cells, suggesting that an alternative indirect and inde-
pendent of the OB-R presence mechanism might be
involved in leptin-mediatedh T E R Te x p r e s s i o nt h r o u g h
JAK/STAT3 pathway. Furthermore, the fact that leptin
repressed the production of TGF-b1, a known negative
regulator of hTERT [47] represents one more step
towards the understanding of the molecular mechanism
of leptin action in HCC and the proof of power of lep-
tin-hTERT axis in the tumorigenic processes. To gain
insight into the biological effects of leptin’s action in the
progression and invasion of HCC, we next examined
leptin’s effect in the production of MMP-1, -9, 13 by
hepatocarcinoma cells. Many secreted MMPs are nearly
absent in healthy, resting tissues, although they are
deregulated in active tissues, as in liver fibrosis and
tumor metastasis [48]. In our study we observed, for the
first time, that leptin is able to suppress MMP-1 expres-
sion and trigger MMP-9 and MMP-13 expression in
HepG2 cells, and this could contribute to a more
favourable environment for invasion and metastasis of
HCC in the cirrhotic liver.
In order to elucidate the signalling cascades in liver
cancer, the regulatory mechanisms of genes altered in
HCC cells need to be determined. In our study, for the
first time to our knowledge, we found that the amount
of acetylated H3, in HCC cells, interacting with leptin
proximal promoter was correlated with the regulation of
leptin gene transcription. The importance of this finding
lies in the fact that histone acetylation is reversible and
thus may have therapeutic potential.
Conclusions
In conclusion, our data revealed, for the first time, that
leptin up-regulates hTERT expression and TA and deci-
phered the molecular mechanisms responsible for their
interaction in HCC, thus establishing a clearer view of
leptin-mediated HCC cell proliferation and progression.
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